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Abstract (100-150 words)  
This is a lethal X-linked disorder of infancy comprising a distinct combination of 
distinctive craniofacial features producing an aged appearance, growth failure, hypotonia, global 
developmental delays, cryptorchidism, and acquired cardiac arrhythmias. The first family was 
identified in Ogden, Utah, with five affected boys in two generations of family members.  A 
mutation was identified as a c.109T>C (p.Ser37Pro) variant in NAA10, a gene encoding the 
catalytic subunit of the major human N-terminal acetyltransferase (NatA). This same mutation 
was identified in a second unrelated family, with three affected boys in two generations. This X-
linked Malformation and Infantile Lethality Syndrome has provisionally been named Ogden 
Syndrome, in honor of the hometown where the first family resides. 
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b. Chapter summary 
There are two unrelated families thus far discovered with a lethal X-linked disorder of 
infancy comprising a distinct combination of an aged appearance, distinctive craniofacial 
features, growth failure hypotonia, global developmental delays, cryptorchidism, and acquired 
cardiac arrhythmias (see Figure 1) [1].  X-chromosome exon sequencing and a 
probabilistic disease-causing variant discovery algorithm identified in these two families the 
same c.109T>C (p.Ser37Pro) variant in NAA10, a gene encoding the catalytic subunit of the 
major human N-terminal acetyltransferase (NatA). The absence of this variant in controls, the 
amino acid conservation of this region of the protein, the predicted disruptive change, and the 
co-occurrence in two unrelated families with the same rare disorder suggest that this mutation is 
necessary for expression of the phenotype. There is significantly impaired biochemical activity 
of the mutant hNaa10p, suggesting that a reduction in acetylation of some unidentified proteins 
by hNaa10p might lead to this disease. This is the first human genetic disorder identified 
resulting from impairment of N-terminal acetylation, one of the most common protein 
modifications in humans. 
  
c. Gene description 
NAA10, a gene encoding the catalytic subunit of the major human N-terminal acetyltransferase 
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(NatA), OMIM entry #300855 for Ogden Syndrome, with alternative title N-terminal 
acetyltransferase Deficiency. 
 
d. Clinical summary with composite figure  
This is an X-linked condition affecting males and characterized by postnatal growth 
failure with developmental delays and dysmorphic features characterized by wrinkled forehead, 
anterior and posterior fontanels, prominent eyes, largedown-slanting palpebral fissures, 
thickened or hooded eyelids, large ears, flared nares, hypoplastic alae nasi, short columella, 
protruding upper lip, and microretrognathia (see Figure 1 and Table 1). There is also delayed 
closing of fontanels, and the boys also have broad great toes. Skin is characterized by 
redundancy or laxity with minimal subcutaneous fat, cutaneous capillary malformations, and 
very fine hair and eyebrows. Death resulted from cardiogenic shock following arrhythmia, which 
was noted in all affected individuals. Several of the boys had structural anomalies of their hearts 
including ventricular septal defect, atrial septal defect, and pulmonary artery stenosis. 
Arrhythmias at the time of death included torsade de pointes, premature ventricular contraction 
(PVC), premature atrial contraction (PAC), supraventricular tachycardia (SVtach), and 
ventricular tachycardia (Vtach). Most of the children had inguinal hernia, and the majority had, at 
least, unilateral cryptorchidism. All had neonatal hypotonia progressing to hypertonia, and 
cerebral atrophy on MRI; several, but not all, had neurogenic scoliosis. Death occurred prior to 2 
years in all cases and prior to 1 year in the majority. There are extensive clinical details for each 
child reported in the original publication [1]. 
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Table 1. Features of the syndrome  
Growth post-natal growth failure 
Development global, severe delays 
Facial wrinkled foreheads 
prominence of eyes, down-sloping palpebral fissures, thickened 
eyelids 
large ears 
flared nares, hypoplastic alae nasi, short columella 
protruding upper lip 
micro-retrognathia 
Skeletal delayed closure of fontanels 
broad great toes 
Integument redundancy / laxity of skin 
minimal subcutaneous fat 
cutaneous capillary malformations 
very fine hair and eyebrows 
Cardiaca structural anomalies (ventricular septal defect, atrial level defect, 
pulmonary artery stenoses) 
arrhythmias (Torsade de points, PVCs, PACs, SVtach, Vtach) 
death usually associated with cardiogenic shock preceded by 
arrhythmia 
Genitala inguinal hernia 
hypo- or cryptorchidism 
Neurologica hypotonia progressing to hypertonia 
cerebral atrophy 
neurogenic scoliosis  
a features of the syndrome demonstrating more variability. Though variable 
findings of the cardiac, genital and neurologic systems were observed, all 
affected individuals manifested some pathologic finding of each. 
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e. Molecular genetics 
A mutation in an enzyme involved in N-terminal acetylation of proteins has thus far been 
associated with this distinct X-linked phenotype in two families (Figure 2), with 8 males who 
carried the hypomorphic hNaa10p p.Ser37Pro allele dying in infancy with cardiomegaly and 
cardiac arrhythmias. N-terminal acetylation is one of the most common protein modifications in 
humans, occurring on approximately 80% of all human proteins [2]. It is catalyzed by several 
distinct NAT-enzyme complexes, of which the major one is the NatA complex [3]. The catalytic 
subunit of the NatA complex, hNaa10p, is essential for survival in the organisms Drosophila 
melanogaster [4], Trypanosoma brucei [5] and Caenorhabditis elegans [6]. It is presumed that 
an amorphic (a null) NAA10 mutation would lead to embryonal lethality in humans, although this 
has not been proven.  
 
f.  Diagnosis and Management 
The diagnosis is made by molecular diagnosis in male infants with the characteristic 
facial appearance, postnatal growth failure and developmental delays. The full spectrum of 
Ogden syndrome is yet to be described, and the phenotypic spectrum will likely expand as other 
mutations in NAA10 or other NATs are found.  As the affected infants have an aged 
appearance, the differential diagnosis should include Hutchinson-Gilford progeria syndrome and 
other progeroid syndromes. However, the autopsies did not reveal any premature 
arteriosclerosis or degeneration of vascular smooth muscle cells (SMCs), as is seen in 
Hutchinson-Gilford progeria syndrome (MIM #176670) [10],[11].  
To date, screening and interventions for individuals affected with Ogden syndrome has 
been largely empiric and without proven benefit to prolonging lifespan. That being said, quality 
of life is likely improved by taking some measures. 
Neuroimaging has been obtained in a number of these children, primarily to screen for 
brain anomalies associated with their hypotonia and growth failure.  In some cases, there was 
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an incidental finding of cerebral atrophy, but there was no radiographic evidence to explain their 
hypotonia or growth failure. 
Baseline echocardiography is recommended as septal defects have been identified in 
several cases. Medical (pharmaceutical) management has been employed to slow the 
progression of congestive heart failure (CHF). Electrocardiography (EKG) is also obtained at the 
time of diagnosis, as fatal dysrhythmias develop with time and eventually lead to the boys’ 
demise. In several cases, the initial EKG has been normal, with evolution of arrhythmias in the 
last months of life. It may be necessary to evaluate them on a monthly basis and be vigilant for 
signs of and symptoms of dysrhythmia/CHF. The arrhythmias have proven difficult to manage, 
though the full spectrum of anti-arrhythmics has not been tested. Individuals have responded to 
episodic cardioversion/defibrillation, but long term treatment has not yet been determined. There 
have been no attempts for more invasive interventions; such as the use of a pacemaker, 
implantable defibrillator or cardiac ablation. 
Careful evaluation for umbilical and inguinal hernia is recommended, with herniorraphy 
suggested in cases where incarceration of the hernia appears likely. 
In at least one individual, intervention for a neurogenic scoliosis was attempted with 
equivocal results. He did not respond to external bracing and rods were surgically placed. 
Unfortunately, he suffered a number of complications from this procedure and there was some 
doubt as to whether he truly benefitted from the therapy. 
Dysphagia, gastroesophageal reflux and malnutrition from decreased caloric intake have 
been commonly observed. Feeding assistance via NG/NJ tube and antacids may be of some 
use. At least one of the affected infants responded well to Nissen fundoplication with a G-tube 
and relieved some of the burden of daily challenges for his parents. 
Though attempted in order to identify a treatable component of their condition, extensive 
laboratory panels assessing digestive function, screening for metabolic decompensation and 
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hormonal dysregulation have not been significantly useful in improving the care or outcome for 
these children. 
 
g. Molecular pathogenesis 
N-terminal acetylation of proteins is catalyzed by N-terminal acetyltransferases (NATs).  
The primary NAT in terms of targeted substrates is the evolutionarily conserved NatA complex 
[2, 3, 12]. The functional impact of N-terminal acetylation remains elusive, but recent data 
suggest a role as a destabilization signal for proteins [13] and in the cellular sorting of nascent 
polypeptides [14]. The human NatA complex is composed of the catalytic subunit hNaa10p 
(hARD1) and the auxiliary subunit hNaa15p (NATH/hNAT1), both essential for its activity in vivo 
[15]. Increased NatA levels have been linked to tumor progression, and depletion of NatA 
subunits from cancer cells induces cell cycle arrest and apoptosis [16]. Human Naa10p is a 
protein of 235 amino acid residues, of which the first 178 residues compose a globular region, 
while the latter 57 residues are predicted to form an unstructured and flexible C-terminal tail 
[17]. Thus, Ser37 is located in a structured part of hNaa10p. For many soluble globular proteins, 
Pro is known to be potentially disruptive for secondary structure elements like the alpha-helix 
and beta-sheets [18]. Thus, although the structure of hNaa10p is undetermined, the p.Ser37Pro 
mutation may indeed affect the structure of hNaa10p and thereby the catalytic activity. Ser37 
and its surrounding residues are highly conserved among eukaryotes [15], suggesting an 
essential function. A SIFT (Sorting Intolerant From Tolerant) analysis predicting whether an 
amino acid substitution affects protein function [19] strongly suggested that the substitution from 
Ser to Pro at position 37 would affect protein function [1]. Therefore, the published data show 
several things, including: 1) strong conservation of Naa10p Ser37, 2) a prediction of structural 
distortion by p.Ser37Pro, and 3) disruption of catalytic activity in the recombinant p.Ser37Pro 
protein in vitro. This implies that the hemizygous males with hNaa10p p.Ser37Pro might have 
impaired NatA function [1]. Thus, a number of protein N-termini might be insufficiently 
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acetylated, including Naa10 substrates that are both co- translationally and post- translationally 
acetylated (e.g., actins). The serious consequences of the p.Ser37Pro mutation therefore might 
be caused by the lack of N-terminal acetylation for one or several proteins requiring this 
modification for full functionality or for maintenance of adequate amounts in the cell. The effect 
of this mutation on specific pathways and cellular functions is still being determined, but 
theoretically, many functions could be involved. Since hNaa10p also has been suggested to 
perform N-lysine (N-epsilon) acetylation of proteins like beta-catenin [7], decreased N-lysine 
acetylation of selected substrates might also cause the observed effects. Finally, proposed non-
catalytic functions of hNaa10p [8, 9] could be affected in the p.Ser37Pro mutant and thereby 
also play a role in the observed phenotypes.  
 
3. Figures 
Figure legends 
Figure 1. Triptych of III-4 from Family 1.  These pictures demonstrate the prominence of 
eyes, down-slanted palpebral fissures, thickened lids, large ears, flared nares, hypoplastic alae 
nasi, short columella, protruding upper lip and micro-retrognathia. 
 
Figure 2. Pedigree drawing and Pictures of Families 1 and 2. A) Pedigree drawing for 
Family 1. SB, stillborn. Genotypes are marked for those in which DNA was available and tested. 
+ is normal variant, mt is rare mutant variant. B) Pictures of five affected/deceased boys in this 
family, showing the aged appearance. C) Pedigree for Family 2. III-2 is the subject most well 
studied in the family. D) Pictures of II-I and III-2 in Family 2. 
 
4. Additional online resources: 
a. Additional clinical illustrations 
See attached pictures. 
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b. Mutations 
Currently, there are no other pathogenic mutations definitively identified in any of 
the other N-terminal acetyltransferase genes.  
c. Additional Text. 
We speculate that other mutations have not been discovered possibly due to 
embryonic lethality of such mutations. 
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